Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

About this update from Insulet Corporation

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans. “At Insulet, we believe diabetes technology should do more and demand less from the people who rely on it every day,” said Ashley McEvoy, President and CEO of Insulet. “The data and innovations we’re sharing at ADA reflect this commitment, showing how Omnipod is advancing AID by improving outcomes, reducing disease burden, and unlocking barriers to AID adoption.” Insulet’s presence at ADA highlights Omnipod’s latest planned innovations, supported by clinical data demonstrating the performance of its next-generation products. This follows the most significant algorithm update in the U.S. since Omnipod 5 launched in 2022. The enhanced Omnipod 5 algorithm features a lower Target Glucose setting for more time in range, updated alarm handling designed for fewer interruptions and increased time in Automated Mode, and integration with Abbott’s FreeStyle Libre 3 Plus sensor. The Company will also share detailed information about STRIVE, EVOLUTION 3, and other milestone studies throughout ADA. STRIVE is the pivotal trial supporting the regulatory submission of the next generation Omnipod 6 Automated Insulin Delivery System. EVOLUTION 3 is the pre-pivotal study evaluating the safety and effectiveness of Insulet’s fully closed-loop system for adults with type 2 diabetes.* Insulet is sponsoring a product theater presentation, The Omnipod Difference: Patient-Centered Simplicity and Breakthrough Algorithm Performance, on Sunday, June 7 from 10:15 – 11:00 AM CT. Speakers will include: Dr. Sufyan Hussain, MA, MB BChir, MRCP, PhD, Diabetes and Endocrine Physician, Guy’s and St Thomas’ Hospital, Adjunct Reader in Diabetes, King’s College London Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics & Director of Pediatric Diabetes Technology Research H. Peter Chase, MD Endowed Chair, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus. Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer at Insulet Insulet will also host two Diabetes Learning Byte sessions at booth 1108 on Saturday, June 6. Advancing...

View stock analysis, news, and events for Insulet Corporation